News Briefs

The FDA recently approved Aduhelm as the first new drug for Alzheimer’s disease in almost 20 years.
June 19, 2021 - 10:53 am

On Monday, June 7, the Food and Drug Administration (FDA) approved Aduhelm (aducanumab) for the treatment of Alzheimer’s disease, a condition that affects over 6 million people in the United States.1 The drug is a first-of-its kind therapy, according to the FDA.

“Currently available therapies only treat symptoms of the disease; this treatment option is the first therapy to target and affect the underlying disease process of Alzheimer’s,” said Patrizia Cavazzoni, MD, director of the FDA’s Center for Drug Evaluation and Research, in a statement.1

The drug is intended to slow the progression of Alzheimer’s disease. It is not a cure.

The news about Aduhelm’s approval is both exciting and controversial. It’s exciting because it is the first new drug approved to treat Alzheimer’s since 2003. It’s controversial because it’s not clear from the clinical trial that the drug will actually work. Last year, an FDA panel concluded there wasn’t enough evidence to prove the drug was effective.

Source: Verywell

News Briefs


What we can learn from the 1918 Flu Pandemic as the Omicron variant spreads
What we can learn from the 1918 Flu Pandemic as the Omicron variant spreads

Historically, most pandemics end within 2 to 3 years as the virus mutates into a less virulent pathogen and the population builds up immunity. This is what happened to the influenza strain behind the 1918 flu pandemic.

Twitter Handle

Copyright © 2021 I Daily Remedy